Prospect: information for the patient
Letrozol Mylan 2.5 mg film-coated tablets EFG
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
1.What is Letrozol Mylan and for what it is used
2.What you need to know before starting to take Letrozol Mylan
3.How to take Letrozol Mylan
4.Possible adverse effects
5.Storage of Letrozol Mylan
6.Contents of the package and additional information
What is Letrozol Mylan and how it works
Letrozol Mylan contains an active ingredient called letrozol. It belongs to a group of medicines called aromatase inhibitors. It is a hormone treatment (or "endocrine") for breast cancer. The growth of breast cancer is usually stimulated by estrogens, which are the female sex hormones. Letrozol Mylan reduces the amount of estrogen by blocking an enzyme ("aromatase") involved in estrogen production and therefore can block the growth of breast cancers that need estrogens to grow. As a result, tumor cells grow more slowly or stop growing and/or spreading to other parts of the body.
What is Letrozol Mylan used for
Letrozol Mylan is used to treat breast cancer in women who have gone through menopause, that is, the cessation of menstrual periods.
It is used to help prevent breast cancer from recurring. It can be used as the first treatment before breast cancer surgery, if immediate surgery is not suitable, or it can be used as the first treatment after breast cancer surgery, or after five years of treatment with tamoxifen. Letrozol Mylan is also used to prevent breast cancer from spreading to other parts of the body in patients with advanced breast cancer.
If you have any questions about how Letrozol Mylan works or why you have been prescribed this medicine, consult your doctor.
Do not take Letrozol Mylan
If any of these cases apply to you,do not take this medicine and inform your doctor.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Letrozol Mylan
If any of these cases apply to you,inform your doctor. Your doctor will take this into account during your treatment with letrozol.
This medicine may cause tendon inflammation or tendon injury (see section 4). If you experience any sign of pain or tendon inflammation, rest the painful area and inform your doctor.
Children and adolescents (under 18 years)
Children and adolescents should not use this medicine.
Older patients (65 years and over)
People 65 years and over may use this medicine at the same dose as for adults.
Taking Letrozol Mylan with other medicines
Inform your doctor or pharmacist of any other medicine you are taking, have recently taken or might have to take, including non-prescription medicines.
Pregnancy, breastfeeding and fertility
Driving and operating machines
If you feel dizzy, tired, sleepy or unwell, do not drive or operate tools or machines until you feel better again.
Letrozol Mylan contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, such as lactose, consult with him before taking this medicine.
This medicine containsless than 23 mg of sodium (1mmol) per ; this is essentially “sodium-free”
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The usual dose is one Letrozol Viatris tablet once a day. If you take Letrozol Viatris at the same time every day, it will help you remember when to take the tablet.
The tablet can be taken with or without food and should be swallowed whole with a glass of water or other liquid.
How long to take Letrozol Viatris
Continue taking Letrozol Viatris every day for the time your doctor tells you to. You may need to take it for months or even years. If you have any doubts about how long you should take Letrozol Viatris, consult your doctor.
Monitoring during treatment with Letrozol Viatris
You should only take this medication under strict medical supervision. Your doctor will periodically check your condition to ensure that the treatment is having the desired effect.
Letrozol Viatris may cause a decrease in bone thickness or bone loss (osteoporosis) due to the decrease in estrogen in the body. Your doctor may decide to perform bone density measurements(a way to monitor osteoporosis) before, during, and after treatment.
If you take more Letrozol Viatris than you should
If you have taken too many Letrozol Viatris tablets, or if someone else has accidentally taken the tablets, contact your doctor or go to the hospital immediately. Show them the packaging of the tablets. You may need medical treatment. You can also call the Toxicology Information Service, Tf:915620420, indicating the medication and the amount taken.
If you forget to take Letrozol Viatris
If you interrupt treatment with Letrozol Viatris
Do not stop taking Letrozol Viatris unless your doctor tells you to. See also the section “How long to take Letrozol Viatris”.
Most side effects are mild to moderate and usually disappear within a few days or weeks of treatment.
Some of these side effects, such as hot flashes, hair loss, or vaginal bleeding, may be due to a lack of estrogen.
Do not be alarmed by this list of possible side effects. You may not experience any of them.
Some side effects may be serious:
Rare(may affect up to 1 in 100 people)
Uncommon(may affect up to 1 in 1,000 people)
Frequency not known(cannot be estimated from available data)
If you experience any of the above, inform your doctor immediately.
Other possible side effects
Very common(may affect more than 1 in 10 people)
If any of these affect you severely, consult your doctor.
Common(may affect up to 1 in 10 people)
If any of these affect you severely, inform your doctor.
Rare(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
– Tendon rupture (connective tissues that connect muscles to bones).
If any of these affect you severely, inform your doctor.
Frequency not known(cannot be estimated from available data)
If this affects you severely, inform your doctor.
Reporting of side effects:
If you experience any type of side effect, consult your doctor, or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use Letrozol Mylan after the expiration date that appears on the packaging after CAD or EXP. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.
The active ingredient is letrozol. Each film-coated tablet contains 2.5 mg of letrozol.
The other components (excipients) are lactose monohydrate (see section 2, "Letrozol Mylan contains lactose and sodium"), microcrystalline cellulose, cornstarch, anhydrous colloidal silica, sodium carboxymethylcellulose (potato) and magnesium stearate. The coating consists of yellow iron oxide (E-172), hypromellose, polydextrose, macrogol, triacetin, yellow quinoline colorant (E-104) and titanium dioxide (E-171).
Appearance of the product and contents of the package
Letrozol Mylan is presented as film-coated tablets. The tablets are dark yellow in color, capsule-shaped, with the inscription "LZ 2.5" on one face and "G" on the other face.
Letrozol Mylan is available in blisters or bottles of 7, 10, 14, 20, 28, 30, 56, 60, 84, 90, 98, 100, 112, 120, 180, 200 and 500 tablets and in perforated single-dose blisters of 30 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Mylan Pharmaceuticals, S.L.
C/ Plom, 2-4, 5th floor
08038 - Barcelona
Spain
Responsible for manufacturing
Delpharm Lille S.A.S
Parc d’activités Roubaix-Est
22 rue de Toufflers – CS 50070
59452 Lys-Lez-Lannoy
France
Or
Mylan Hungary Kft.
Mylan utca 1
Komárom, 2900
Hungary
This medicine is authorized in the member states of the European Economic Area with the following names:
Austria:Letrozol Arcana
Cyprus:Letrozole / Generics
Czech Republic:Letmylan
Denmark:Letrozol Mylan
Finland:Letrozol Mylan
France:Letrozole Mylan
Greece:Letrozole Mylan
Ireland:Letrozole Mylan
Italy:Letrozolo Mylan Generics
Netherlands:Letrozole Mylan
Norway:Letrozol Mylan
Portugal:Letrozol Mylan
Spain:Letrozol Mylan
Sweden:Letrozol Mylan
Last revision date of this leaflet:12/2019
Further information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.